-
公开(公告)号：US20230357233A1
公开(公告)日：2023-11-09
申请号：US18042872
申请日：2021-08-26
发明人： Xing DAI , Hong YANG , Xianhai HUANG , Haotao NIU , Zixing HAN , Zhenwu WANG , Qiang ZHANG , Yanqin LIU , Yueheng JIANG , Liangshan TAO , Jifang WENG , Zhe SHI , Yaolin WANG
IPC分类号： C07D471/04 , A61K45/06 , C07D519/00
CPC分类号： C07D471/04 , A61K45/06 , C07D519/00
摘要： Provided herein are novel compounds, for example, compounds having a Formula (I), Formula (A), Formula (II), Formula (III), Formula (IV), or Formula (V), or a pharmaceutically acceptable salt thereof. Also provided herein are methods of preparing the compounds and methods of using the compounds, for example, in inhibiting KRASG12D in a cancer cell, and/or in treating various cancer such as pancreatic cancer, colorectal cancer, lung cancer (e.g., non-small cell lung cancer) or endometrial cancer.
-
公开(公告)号：US20240140929A1
公开(公告)日：2024-05-02
申请号：US18268681
申请日：2021-12-22
发明人： Xing DAI , Xianhai HUANG , Hong YANG , Zixing HAN , Haotao NIU , Jifang WENG , Zhe SHI , Yanqin LIU , Yueheng JIANG , Yaolin WANG
IPC分类号： C07D401/12 , C07D213/75 , C07D237/24 , C07D253/075 , C07D401/14 , C07D405/14 , C07D413/14 , C07D417/12 , C07D417/14 , C07D471/04 , C07D513/04
CPC分类号： C07D401/12 , C07D213/75 , C07D237/24 , C07D253/075 , C07D401/14 , C07D405/14 , C07D413/14 , C07D417/12 , C07D417/14 , C07D471/04 , C07D513/04
摘要： Provided herein are novel compounds, for example, compounds having a Formula (I), or a pharmaceutically acceptable N salt thereof. Also provided herein are methods of preparing the compounds and methods of using the compounds, for example, in inhibiting TYK2, and/or function of IL-12, IL-23 and/or INF-alpha, and/or in treating various associated diseases or disorders.
-
公开(公告)号：US20220371996A1
公开(公告)日：2022-11-24
申请号：US17748134
申请日：2022-05-19
发明人： Xing DAI , Yueheng JIANG
IPC分类号： C07D213/70 , A61K31/426 , A61K31/522 , A61K31/4418
摘要： Provided herein are compounds, salts, crystalline forms, and pharmaceutical compositions that are related to thiobutyrate compounds, such as Compound (1) and its salts (such as sodium, potassium, and calcium salt), as well as methods of preparing the same. Also provided herein are methods of using the compounds, salts, crystalline forms, and pharmaceutical compositions for the treatment of diseases or disorders, such as gout and hyperuricemia.
-
4.发明公开公开(公告)号：US20240208967A1
公开(公告)日：2024-06-27
申请号：US18515890
申请日：2023-11-21
发明人： Yueheng JIANG
IPC分类号： C07D471/04 , A61K31/437 , A61K31/506 , A61P35/02 , A61P35/04 , C07D401/04 , C07D401/14 , C07D403/04 , C07D403/14 , C07D405/14 , C07D413/04 , C07D417/04
CPC分类号： C07D471/04 , A61K31/437 , A61K31/506 , A61P35/02 , A61P35/04 , C07D401/04 , C07D401/14 , C07D403/04 , C07D403/14 , C07D405/14 , C07D413/04 , C07D417/04
摘要： The present invention disclosed a class of pyrimidine or pyridine compounds, pharmaceutically acceptable salts, stereoisomers, prodrugs and solvates thereof, preparation method therefor and pharmaceutical compositions and pharmaceutical uses thereof. See e.g., Formula I below. The compounds can inhibit the variants of EGFR (Epidermis Growth Factor Receptor) proteinases, and therefore can inhibit the growth of a variety of tumor cells effectively. The compounds can be used to prepare antitumor drugs, used for the treatment, combined therapy or prevention of various different cancers. The compounds can overcome the drug resistance induced by the existing first-generation EGFR inhibitors such as gefitinib, erlotinib and so on. Particularly, the compounds can be used to prepare drugs for treating or preventing diseases, disturbances, disorders or conditions mediated by epidermis growth factor receptor variants (such as L858R activated mutants, Exon19 deletion activated mutants and T790M resistant mutants).
-
公开(公告)号：US20230263782A1
公开(公告)日：2023-08-24
申请号：US18010735
申请日：2021-06-18
发明人： Xing DAI , Xiaomei WANG , Yanqin LIU , Yueheng JIANG , Yaolin WANG
IPC分类号： A61K31/437 , A61K9/16 , A61K45/06 , A61K9/20 , A61K47/18
CPC分类号： A61K31/437 , A61K9/1694 , A61K45/06 , A61K9/2013 , A61K9/2018 , A61K9/2027 , A61K9/2054 , A61K47/18
摘要： Provided herein are compounds, salts, crystalline forms, and pharmaceutical compositions that are related to Selective Estrogen Receptor Degraders, as well as methods of preparing the same. Also provided herein are methods of using the compounds, salts, crystalline forms, and pharmaceutical compositions for the treatment of diseases or disorders, such as breast cancer.
-
公开(公告)号：US20220213066A1
公开(公告)日：2022-07-07
申请号：US17611458
申请日：2020-05-15
发明人： Xing DAI , Yueheng JIANG , Yanqin LIU
IPC分类号： C07D403/04
摘要： The present invention relates to a salt of a Compound 1 and polymorphs thereof, and pharmaceutical compositions containing the same, wherein the salt is preferably hydrochloride, phosphate, tosilate, benzene sulfonate, succinate, sulfate, monohydrobromate, dihydrobromate, etc. The present invention further relates to methods for preparing the described substances, their uses, and pharmaceutical preparations containing these salts and crystalline forms.
-
公开(公告)号：US20230027952A1
公开(公告)日：2023-01-26
申请号：US17779476
申请日：2020-11-23
发明人： Xing DAI , Yueheng JIANG , Yanqin LIU
IPC分类号： C07D405/12 , A61K45/06 , A61K31/4433 , A61P35/00 , A61P31/10
摘要： Provided herein are compounds, salts, crystalline forms, and pharmaceutical compositions that are related to IDO inhibitors, in particular, Compound 1,1-(5-((4-chlorophenyl)amino)-6-(ethyl(tetrahydro-2H-pyran-4-yl)amino)pyridin-3-yl)cyclobu tane-1-carboxylic acid. Also provided are methods of treating a disease or disorder such as a cancer or infectious disease that comprises administering to a subject in need thereof one or more of the compounds or compositions of the present disclosure.
-
公开(公告)号：US20220226328A1
公开(公告)日：2022-07-21
申请号：US17591816
申请日：2022-02-03
发明人： Xing DAI , Yueheng JIANG , Yanqin LIU
IPC分类号： A61K31/519 , A61K45/06 , C07D471/04
摘要： Provided herein are compounds, crystalline forms, and pharmaceutical compositions of Compound 1 and/or Compound 2. Also provided are methods of treating a disease or disorder such as a cancer or infectious disease that comprises administering to a subject in need thereof one or more of the compounds or compositions of the present disclosure.
-
公开(公告)号：US20210355125A1
公开(公告)日：2021-11-18
申请号：US17365503
申请日：2021-07-01
发明人： Xing DAI , Yaolin WANG , Yueheng JIANG , Yanqin LIU , Zhe SHI , Zhenwu WANG , Liangshan TAO , Zixing HAN , Haotao NIU , Jifang WENG
IPC分类号： C07D471/04 , A61P35/00 , A61K33/243 , A61K31/282 , A61K31/438 , A61K31/519 , C07D519/00
摘要： Provided herein are novel compounds, for example, compounds having a Formula (I) or Formula (II), or a pharmaceutically acceptable salt thereof. Also provided herein are methods of preparing the compounds and methods of using the compounds, for example, in inhibiting KRAS G12C in a cell, and/or in treating various cancer such as pancreatic cancer, endometrial cancer, colorectal cancer, or lung cancer (e.g., non-small cell lung cancer).
-
公开(公告)号：US20230357260A1
公开(公告)日：2023-11-09
申请号：US18316471
申请日：2023-05-12
发明人： Xing DAI , Yaolin WANG , Yueheng JIANG , Yanqin LIU , Haotao NIU , Zhenwu WANG , Zixing HAN , Liangshan TAO , Jifang WENG , Zhe SHI
IPC分类号： C07D493/08 , C07D401/14 , C07D405/14 , C07D417/14 , C07D487/04
CPC分类号： C07D493/08 , C07D401/14 , C07D405/14 , C07D417/14 , C07D487/04
摘要： Provided herein are novel heterocyclic compounds, for example, compounds having Formula I. Also provided herein are methods of preparing the compounds and methods of using the same, for example, in inhibiting TGF-beta mediated signaling and/or for treating cancer.
-
-
-
-
-
-
-
-
-
搜索结果
19 条记录 (耗时 0.016 秒)
